课题基金 / 基金详情

HUPERZINE

HUPERZINE
石杉碱
批准号:
7378679
负责人:
Thomas O Obisesan
金额:
$3.98万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-07-15 至 2007-02-28

项目摘要

项目成果

Thomas O Obisesan的其他基金

相似基金

相关文献

中文摘要
翻译
本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者(PI)可能已经从另一个NIH来源获得了主要资金,因此可以在其他CRISP条目中表示。列出的机构是中心的,不一定是研究者的机构。石杉碱A是从中药石杉中提取的天然胆碱酯酶抑制剂。有证据表明,与目前使用的胆碱酯酶抑制剂相比,石杉碱A在对症疗效方面可能更有利。此外,石杉碱A具有抗氧化和神经保护特性,这表明它可能有助于治疗阿尔茨海默病(AD)。这种药物目前在美国作为一种营养药品,被一些美国临床医生用于治疗阿尔茨海默病。然而,在中国以外,尚无对其毒性和疗效进行评估的对照临床试验。主要目的是确定200ug石杉碱A治疗可改善AD患者的认知功能。次要目的是:确定400ug剂量石杉碱A治疗是否能改善AD患者的认知功能。确定石杉碱A治疗对AD患者总体临床状况、日常生活活动和行为的影响。评价200ug bid和400ug bid石杉碱A对AD的耐受性。探讨石杉碱A治疗AD患者血胆碱酯酶活性与认知功能的关系。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata. There is eveidence that huperine A may compare favorably in symptomatic efficacy to cholinesterase inhibitors currently in use. In addition, huperzine A has antioxidant and neuroprotective properties that suggest that it may be useful as a disease-modifying treatment for Alzheimer's disease (AD). the drug is currently available as s nutriceutical in this country, and is being used by some U.S. clinicans to treat AD. However, ther have been no controlled clinical trails outside China assessing its toxicity and efficacy. The primary aim is to determine treatment with huperzine A 200ug bid improves cognitive function in patients with AD. Secondary Aims are: To determine whether treatment with huperzine A 400ug bid improves cognitive function in patients with AD. To determine the effect of huperzine A treatment on global clinical status, activities of daily living, and behavior in AD. To evaluate the tolerability of huperzine A treatment at dosages of 200ug bid and 400ug bid in AD. To determine the relationship between blood cholinesterase activity and cognitive function in AD patients treated with huperzine A.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genes, Exercise, Neurocognitive and Neurodegeneration: Community-Based Approach
  • 批准号:
    8644082
  • 项目类别:
  • 资助金额:
    $55.5万
  • 财政年份:
    2014
  • 负责人:
    Thomas O Obisesan
  • 依托单位:
Genes, Exercise, Neurocognitive and Neurodegeneration: Community-Based Approach
  • 批准号:
    8890725
  • 项目类别:
  • 资助金额:
    $53.89万
  • 财政年份:
    2014
  • 负责人:
    Thomas O Obisesan
  • 依托单位:
Genes, Exercise, Neurocognitive and Neurodegeneration: Community-Based Approach
  • 批准号:
    9352907
  • 项目类别:
  • 资助金额:
    $14.64万
  • 财政年份:
    2014
  • 负责人:
    Thomas O Obisesan
  • 依托单位:
Genes, Exercise, Neurocognitive and Neurodegeneration: Community-Based Approach
  • 批准号:
    9277339
  • 项目类别:
  • 资助金额:
    $55.24万
  • 财政年份:
    2014
  • 负责人:
    Thomas O Obisesan
  • 依托单位:
国内基金
海外基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
  • 批准号:
    81000622
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2010
  • 负责人:
    梁胜
  • 依托单位:
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
  • 批准号:
    31060293
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    26.0万元
  • 批准年份:
    2010
  • 负责人:
    郭亚芬
  • 依托单位:
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究